Oral treatment with PD-0200347, an α2δ ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes

Arthritis and Rheumatism

Volumn 52, Issue 2, 2005, Pages 488-500

  Boileau, Christelle ^a   Martel Pelletier, Johanne ^a   Brunet, Julie ^a   Tardif, Ginette ^a   Schrier, Denis ^b   Flory, Craig ^b   El Kattan, Ayman ^b   Boily, Martin ^a   Pelletier, Jean Pierre ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; COLLAGENASE 3; GABAPENTIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERSTITIAL COLLAGENASE; LIGAND; MESSENGER RNA; METALLOPROTEINASE; PD 0200347; PLACEBO; PREGABALIN; RNA; STROMELYSIN; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; FEMUR CONDYLE; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KNEE OSTEOARTHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TISSUE SECTION;

ADMINISTRATION, ORAL; AMINES; ANIMALS; CARTILAGE, ARTICULAR; CHONDROCYTES; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOGS; GAMMA-AMINOBUTYRIC ACID; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; METALLOPROTEASES; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; OSTEOARTHRITIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 13444252339     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20809     Document Type: Article

References (52)

1. Pelletier JP, Martel-Pelletier J, Howell DS. Etiopathogenesis of osteoarthritis. In: WJ Koopman, editor. Arthritis and allied conditions: a textbook of rheumatology. Baltimore: Lippincott, Williams & Wilkins; 2001. p. 2195-245.
2. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets [review]. Arthritis Rheum 2001;44:1237-47.
3. Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, Basbaum AI. Intraneuronal substance P contributes to the severity of experimental arthritis. Science 1984;226:547-9.
4. Lotz M, Carson DA, Vaughan JH. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 1987;235:893-5.
5. Iannone F, Lapadula G. Neuropeptides and human osteoarthritis. J Rheumatol 1998;25:386-8.
6. Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 1988;241:1218-21.
7. Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 2003;25:2506-38.
8. Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60:1274-83.
9. Attal N, Brasseur L, Parker F, Chauvin M, Bouhassira D. Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. Eur J Neurol 1998;40:191-200.
10. Lu Y, Westlund KN. Gabapentin attenuates nociceptive behaviors in an acute arthritis model in rats. J Pharmacol Exp Ther 1999;290:214-9.
11. Kocsis JD, Honmou O. Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve. Neurosci Lett 1994;169:181-4.
12. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J Biol Chem 1996;271:5768-76.
13. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42:229-36.
14. Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 2002;45:171-90.
15. Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices. Pain 2001;93:191-6.
16. Gu Y, Huang LY. Gabapentin actions on N-methyl-D-aspartate receptor channels are protein kinase C-dependent. Pain 2001;93:85-92.
17. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29:233-49.
18. Tanaka S, Hamanishi C, Kikuchi H, Fukuda K. Factors related to degradation of articular cartilage in osteoarthritis: a review. Semin Arthritis Rheum 1998;27:392-9.
19. Reuben PM, Brogley MA, Sun Y, Cheung HS. Molecular mechanism of the induction of metalloproteinases 1 and 3 in human fibroblasts by basic calcium phosphate crystals: role of calcium-dependent protein kinase C α. J Biol Chem 2002;277:15190-8.
20. Fernandes JC, Martel-Pelletier J, Otterness IG, Lopez-Anaya A, Mineau F, Tardif G, et al. Effects of tenidap on canine experimental osteoarthritis. I. Morphologic and metalloprotease analysis. Arthritis Rheum 1995;38:1290-303.
21. Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, et al. In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum 2003;48:1582-93.
22. Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971;53:523-37.
23. Tardif G, Hum D, Pelletier JP, Boileau C, Martel-Pelletier J. Differential gene expression and regulation of bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis Rheum 2004;50:2521-30.
24. Pelletier JP, Lascau-Coman V, Jovanovic D, Fernandes JC, Manning P, Currie MG, et al. Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. J Rheumatol 1999;26:2002-14.
25. Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression. Arthritis Rheum 1996;39:1535-44.
26. Pelletier JP, Mineau F, Raynauld JP, Woessner JF Jr, Gunja-Smith Z, Martel-Pelletier J. Intraarticular injections with methylprednisolone acetate reduce osteoarthritic lesions in parallel with chondrocyte stromelysin synthesis in experimental osteoarthritis. Arthritis Rheum 1994;37:414-23.
27. Brandt KD, Schauwecker DS, Dansereau S, Meyer J, O'Connor B, Myers SL. Bone scintigraphy in the canine cruciate deficiency model of osteoarthritis: comparison of the unstable and contralateral knee. J Rheumatol 1997;24:140-5.
28. Pelletier JP, Martel-Pelletier J. Cartilage degradation by neutral proteoglycanases in experimental osteoarthritis: suppression by steroids. Arthritis Rheum 1985;28:1393-401.
29. Pelletier JP, Martel-Pelletier J, Howell DS, Ghandur-Mnaymneh L, Enis JE, Woessner JF Jr. Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis Rheum 1983;26:63-8.
30. Vincenti MP, Coon CI, Lee O, Brinckerhoff CE. Regulation of collagenase gene expression by IL-1β requires transcriptional and post-transcriptional mechanisms. Nucleic Acids Res 1994;22:4818-27.
31. Kadota K, Tominaga D, Asai R, Takahasi K. Correlation analysis of mRNA and protein abundances in human tissues. Genome Letters 2003;22:139-48.
32. Reboul P, Pelletier JP, Tardif G, Cloutier JM, Martel-Pelletier J. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes: a role in osteoarthritis. J Clin Invest 1996;97:2011-9.
33. Tardif G, Pelletier JP, Dupuis M, Geng C, Cloutier JM, Martel-Pelletier J. Collagenase 3 production by human osteoarthritic chondrocytes in response to growth factors and cytokines is a function of the physiological state of the cells. Arthritis Rheum 1999;42:1147-58.
34. Aigner T, Kim HA. Apoptosis and cellular vitality: issues in osteoarthritic cartilage degeneration [review]. Arthritis Rheum 2002;46:1986-96.
35. Tolboom TC, Pieterman E, van der Laan WH, Toes RE, Huidekoper AL, Nelissen RG, et al. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis 2002;61:975-80.
36. Stove J, Gerlach C, Huch K, Gunther KP, Brenner R, Puhl W, et al. Gene expression of stromelysin and aggrecan in osteoarthritic cartilage. Pathobiology 2001;69:333-8.
37. Amin AR, Dave M, Attur M, Abramson SB. COX-2, NO, and cartilage damage and repair. Curr Rheumatol Rep 2000;2:447-53.
38. Nishida K, Doi T, Matsuo M, Ishiwari Y, Tsujigiwa H, Yoshida A, et al. Involvement of nitric oxide in chondrocyte cell death in chondro-osteophyte formation. Osteoarthritis Cartilage 2001;9:232-7.
39. Jarvinen TA, Moilanen T, Jarvinen TL, Moilanen E. Nitric oxide mediates interleukin-1 induced inhibition of glycosaminoglycan synthesis in rat articular cartilage. Mediators Inflamm 1995;4:107-11.
40. Murrell GA, Jang D, Williams RJ. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995;206:15-21.
41. Taskiran D, Stefanovic-Racic M, Georgescu HI, Evans CH. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun 1994;200:142-8.
42. Shimoyama N, Shimoyama M, Davis AM, Inturrisi CE, Elliott KJ. Spinal gabapentin is antinociceptive in the rat formalin test. Neurosci Lett 1997;222:65-7.
43. Carlton SM, Zhou S. Attenuation of formalin-induced nociceptive behaviors following local peripheral injection of gabapentin. Pain 1998;76:201-7.
44. Matucci-Cerinic M, Partsch G. The contribution of the peripheral nervous system and the neuropeptide network to the development of synovial inflammation. Clin Exp Rheumatol 1992;10:211-5.
45. Fortier LA, Nixon AJ. Distributional changes in substance P nociceptive fiber patterns in naturally osteoarthritic articulations. J Rheumatol 1997;24:524-30.
46. Halliday DA, McNeil JD, Betts WH, Scicchitano R. The substance P fragment SP-(7-11) increases prostaglandin E2, intracellular Ca2+ and collagenase production in bovine articular chondrocytes. Biochem J 1993;292:57-62.
47. Wajima Z, Hua XY, Yaksh TL. Inhibition of spinal protein kinase C blocks substance P-mediated hyperalgesia. Brain Res 2000;877:314-21.
48. Sliva D, English D, Lyons D, Lloyd FP Jr. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-κB. Biochem Biophys Res Commun 2002;290:552-7.
49. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol 1997;15:519-26.
50. Bond M, Chase AJ, Baker AH, Newby AC. Inhibition of transcription factor NF-κ reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res 2001;50:556-65.
51. Pelletier JP, Boileau C, Brunet J, Mineau F, Tardif G, Schrier D, et al. Oral treatment with PD 200347, an α2γ ligand, reduces the development of experimental osteoarthritis by inhibiting chondrocytes, metalloproteases and iNOS gene expression and synthesis [abstract]. Ann Rheum Dis 2004;63:S63.
52. Kopp UC, Farley DM, Cicha MZ, Smith LA. Activation of renal mechanosensitive neurons involves bradykinin, protein kinase C, PGE(2), and substance P. Am J Physiol Regul Integr Comp Physiol 2000;278:R937-46.